Innovimmune Pursues Pharma Partners, Shuns VCs
Summary
Gaweco’s startup is looking for pharma partners even though it hasn’t locked up its patent portfolio or even completed animal trials of its two drug candidates.ROR-gamma (retinoid-related orphan receptor-gamma) is a receptor inside the nucleus of cells that regulates the production of proteins that have been implicated in several inflammatory and autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.And last December, Pfizer (NYSE: PFE) entered into a $217 million research pact with Swedish biotech Karo Bio that was centered around ROR-gamma.Gaweco justifies that approach by pointing to the fact that once patents are issued on a novel drug, a company generally has no more than 20 years to capitalize on it before it becomes vulnerable to generic competition.“Don’t waste the opportunity to get the most bang for your buck.” Gaweco’s approach to entrepreneurship and drug development was shaped by more than a decade of working in Big Pharma.
Classifications
AskAI Classifications
LabelsLinked Companies
